GLP-3 is a high-purity peptide offered in a 10mg lyophilized powder format, intended strictly for laboratory research and development purposes. Manufactured to exceed 99% purity and tested using both HPLC and LC-MS protocols, this peptide is supplied in a sterile, sealed vial to ensure stability and integrity.
Recent research & studies
- Primary signet-ring carcinoma of the urinary bladder: A case report and mini review of literature.
Primary signet ring cell carcinoma (SRCC) of the urinary bladder is an exceptionally rare and aggressive malignancy. We report a case of a 60-year-old man presenting with painless gross hematuria, urinary frequency, and dysuria. Imaging and cystoscopy revealed a bladder…
- A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive…
- A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.
- Design of a metabolically-stable peptide therapeutic with triple-hormone-receptor agonist activity.
Peptide-based therapeutics such as tirzepatide and semaglutide target the neuroendocrine system to remediate both diabetes and obesity. In addition to integrating the complementary actions of two endogenous metabolically related hormones targeting glucagon-like peptide-1 and glucagon receptors (GLP-1R and GCGR), the…
- Correction to: Modern and multidisciplinary care in polycythemia vera.
- A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will last about 80 weeks.
These are third-party research studies presented for informational purposes. They are not endorsements and do not constitute medical advice or claims about any product.
